CLINICAL_TRIALS
trial_result
· 2015-01-08
Clinical Trial Update: Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers [Phase 1]
Summary
A Phase 1 trial assessing tolerability and pharmacokinetics of a single 900 mg oral dose of BIA 2-093 with oxcarbazepine in healthy volunteers.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bial - Portela C S.A. | Conditions: Epilepsy | Phase 1 | Status: COMPLETED | Results posted: 2015-01-08